Susan Galbraith, MD, PhD, head, Oncology Innovative Medicine, AstraZeneca, discusses updated data from the ongoing phase I/II AURA study. This study aims to evaluate AZD9291 for patients previously treated with an EGFR TKI with advanced non-small cell lung cancer (NSCLC) with the T790M mutation.

The confirmed overall response rate was 70% in patients treated with 80 mg of AZD9291. Since the 2014 ASCO Annual Meeting, results have been updated to show that responses are durable — median PFS is 9.6 months. Currently, Galbraith says, the only option for this group of patients is chemotherapy, which elicits PFS of 3-4 months.

Galbraith also notes that AZD9291 is associated with reduced rates of rash and diarrhea compared with chemotherapy.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

ESMO Congress

Susan Galbraith, MD, PhD, head, Oncology Innovative Medicine, AstraZeneca, discusses updated data from the ongoing phase I/II AURA study looking at AZD9291 for NSCLC.

Dr. Galbraith Discusses Phase I/II Results for AZD9291 in Advanced NSCLC